|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 12:214922018.
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hernandez-Aya LF and Gonzalez-Angulo AM:
Adjuvant systemic therapies in breast cancer. Surg Clin North Am.
93:473–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clark GM, Osborne CK and McGuire WL:
Correlations between estrogen receptor, progesterone receptor, and
patient characteristics in human breast cancer. J Clin Oncol.
2:1102–1109. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dorssers LC, Van der Flier S, Brinkman A,
van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV and
Foekens JA: Tamoxifen resistance in breast cancer: Elucidating
mechanisms. Drugs. 61:1721–1733. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hassan MS, Ansari J, Spooner D and Hussain
SA: Chemotherapy for breast cancer (Review). Oncol Rep.
24:1121–1131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mincey BA, Palmieri FM and Perez EA:
Adjuvant therapy for breast cancer: Recommendations for management
based on consensus review and recent clinical trials. Oncologist.
7:246–250. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rowinsky EK: The development and clinical
utility of the taxane class of antimicrotubule chemotherapy agents.
Annu Rev Med. 48:353–374. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schiff PB and Horwitz SB: Taxol stabilizes
microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA.
77:1561–1565. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Woods CM, Zhu J, McQueney PA, Bollag D and
Lazarides E: Taxol-induced mitotic block triggers rapid onset of a
p53-independent apoptotic pathway. Mol Med. 1:506–526. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jordan MA, Wendell K, Gardiner S, Derry
WB, Copp H and Wilson L: Mitotic block induced in HeLa cells by low
concentrations of paclitaxel (Taxol) results in abnormal mitotic
exit and apoptotic cell death. Cancer Res. 56:816–825.
1996.PubMed/NCBI
|
|
12
|
Wang TH, Wang HS and Soong YK:
Paclitaxel-induced cell death: Where the cell cycle and apoptosis
come together. Cancer. 88:2619–2628. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Crown J and O'Leary M: The taxanes: An
update. Lancet. 355:1176–1178. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Esin E and Yalcin S: Neuropathic cancer
pain: What we are dealing with? How to manage it? Onco Targets
Ther. 7:599–618. 2014.PubMed/NCBI
|
|
15
|
Hershman DL, Lacchetti C, Dworkin RH,
Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino
A, Lustberg MB, et al: ; American Society of Clinical Oncology:
Prevention and management of chemotherapy-induced peripheral
neuropathy in survivors of adult cancers: American Society of
Clinical Oncology clinical practice guideline. J Clin Oncol.
32:1941–1967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parvathy SS and Masocha W: Matrix
metalloproteinase inhibitor COL-3 prevents the development of
paclitaxel-induced hyperalgesia in mice. Medical principles and
practice: International journal of the Kuwait University. Health
Sci Cent. 22:35–41. 2013.
|
|
17
|
Golub LM, Ramamurthy NS, McNamara TF,
Greenwald RA and Rifkin BR: Tetracyclines inhibit connective tissue
breakdown: new therapeutic Implications for an old family of drugs.
Crit Rev Oral Biol Med. 2:297–321. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Golub LM, Suomalainen K and Sorsa T: Host
modulation with tetracyclines and their chemically modified
analogues. Curr Opin Dent. 2:80–90. 1992.PubMed/NCBI
|
|
19
|
Gu Y, Lee HM, Simon SR and Golub LM:
Chemically modified tetracycline-3 (CMT-3): A novel inhibitor of
the serine proteinase, elastase. Pharmacol Res. 64:595–601. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lokeshwar BL: Chemically modified
non-antimicrobial tetracyclines are multifunctional drugs against
advanced cancers. Pharmacol Res. 63:146–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Al Saleh S, Al Mulla F and Luqmani YA:
Estrogen receptor silencing induces epithelial to mesenchymal
transition in human breast cancer cells. PLoS One. 6:e206102011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luqmani YA, Al Azmi A, Al Bader M, Abraham
G and El Zawahri M: Modification of gene expression induced by
siRNA targeting of estrogen receptor alpha in MCF7 human breast
cancer cells. Int J Oncol. 34:231–242. 2009.PubMed/NCBI
|
|
23
|
Khajah MA, Al Saleh S, Mathew PM and
Luqmani YA: Differential effect of growth factors on invasion and
proliferation of endocrine resistant breast cancer cells. PLoS One.
7:e418472012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khajah MA, Mathew PM and Luqmani YA:
Inhibitors of PI3K/ERK1/2/p38 MAPK show preferential activity
against endocrine-resistant breast cancer cells. Oncol Res.
25:1283–1295. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khajah MA, Mathew PM, Alam-Eldin NS and
Luqmani YA: Bleb formation is induced by alkaline but not acidic pH
in estrogen receptor silenced breast cancer cells. Int J Oncol.
46:1685–1698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chou TC, Tan QH and Sirotnak FM:
Quantitation of the synergistic interaction of edatrexate and
cisplatin in vitro. Cancer Chemother Pharmacol. 31:259–264. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Al Saleh S, Sharaf LH and Luqmani YA:
Signalling pathways involved in endocrine resistance in breast
cancer and associations with epithelial to mesenchymal transition
(Review). Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI
|
|
29
|
Krajewski S, Krajewska M, Turner BC, Pratt
C, Howard B, Zapata JM, Frenkel V, Robertson S, Ionov Y, Yamamoto
H, et al: Prognostic significance of apoptosis regulators in breast
cancer. Endocr Relat Cancer. 6:29–40. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee JJ and Swain SM: Peripheral neuropathy
induced by microtubule-stabilizing agents. J Clin Oncol.
24:1633–1642. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Y, Yang C and Wang ZJ:
Proteinase-activated receptor 2 sensitizes transient receptor
potential vanilloid 1, transient receptor potential vanilloid 4,
and transient receptor potential ankyrin 1 in paclitaxel-induced
neuropathic pain. Neuroscience. 193:440–451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishida K, Kuchiiwa S, Oiso S, Futagawa T,
Masuda S, Takeda Y and Yamada K: Up-regulation of matrix
metalloproteinase-3 in the dorsal root ganglion of rats with
paclitaxel-induced neuropathy. Cancer Sci. 99:1618–1625. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
D'Agostino P, Ferlazzo V, Milano S, La
Rosa M, Di Bella G, Caruso R, Barbera C, Grimaudo S, Tolomeo M, Feo
S, et al: Chemically modified tetracyclines induce cytotoxic
effects against J774 tumour cell line by activating the apoptotic
pathway. Int Immunopharmacol. 3:63–73. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liebmann JE, Cook JA, Lipschultz C, Teague
D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel
(Taxol) in human tumour cell lines. Br J Cancer. 68:1104–1109.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu K, Cang S, Ma Y and Chiao JW:
Synergistic effect of paclitaxel and epigenetic agent phenethyl
isothiocyanate on growth inhibition, cell cycle arrest and
apoptosis in breast cancer cells. Cancer Cell Int. 13:102013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tommasi S, Mangia A, Lacalamita R,
Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N,
Latorre A, Lorusso V, et al: Cytoskeleton and paclitaxel
sensitivity in breast cancer: The role of beta-tubulins. Int J
Cancer. 120:2078–2085. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zasadil LM, Andersen KA, Yeum D, Rocque
GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME and Weaver BA:
Cytotoxicity of paclitaxel in breast cancer is due to chromosome
missegregation on multipolar spindles. Sci Transl Med.
6:229ra432014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Izbicka E, Campos D, Carrizales G and
Patnaik A: Biomarkers of anticancer activity of R115777
(Tipifarnib, Zarnestra) in human breast cancer models in vitro.
Anticancer Res. 25:3215–3223. 2005.PubMed/NCBI
|
|
39
|
Tokuda E, Seino Y, Arakawa A, Saito M,
Kasumi F, Hayashi S and Yamaguchi Y: Estrogen receptor-α directly
regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for
breast cancer. Breast Cancer Res Treat. 133:427–436. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gu Y, Lee HM, Roemer EJ, Musacchia L,
Golub LM and Simon SR: Inhibition of tumor cell invasiveness by
chemically modified tetracyclines. Curr Med Chem. 8:261–270. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lokeshwar BL, Escatel E and Zhu B:
Cytotoxic activity and inhibition of tumor cell invasion by
derivatives of a chemically modified tetracycline CMT-3 (COL-3).
Curr Med Chem. 8:271–279. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lokeshwar BL, Selzer MG, Zhu BQ, Block NL
and Golub LM: Inhibition of cell proliferation, invasion, tumor
growth and metastasis by an oral non-antimicrobial tetracycline
analog (COL-3) in a metastatic prostate cancer model. Int J Cancer.
98:297–309. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meng Q, Xu J, Goldberg ID, Rosen EM,
Greenwald RA and Fan S: Influence of chemically modified
tetracyclines on proliferation, invasion and migration properties
of MDA-MB-468 human breast cancer cells. Clin Exp. 18:139–146.
2000. View Article : Google Scholar
|
|
44
|
Zhao L, Xu J, Yang Y, Chong Y, Liu C, Jiao
Y and Fan S: Inhibitory impacts of chemically modified
tetracycline-3 and underlying mechanism in human cervical cancer
cells. Anticancer Drugs. 24:799–809. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ward SJ, McAllister SD, Kawamura R, Murase
R, Neelakantan H and Walker EA: Cannabidiol inhibits
paclitaxel-induced neuropathic pain through 5-HT(1A) receptors
without diminishing nervous system function or chemotherapy
efficacy. Br J Pharmacol. 171:636–645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ward SJ, Ramirez MD, Neelakantan H and
Walker EA: Cannabidiol prevents the development of cold and
mechanical allodynia in paclitaxel-treated female C57Bl6 mice.
Anesth Analg. 113:947–950. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bhalla K, Ibrado AM, Tourkina E, Tang C,
Mahoney ME and Huang Y: Taxol induces internucleosomal DNA
fragmentation associated with programmed cell death in human
myeloid leukemia cells. Leukemia. 7:563–568. 1993.PubMed/NCBI
|
|
48
|
Fan W: Possible mechanisms of
paclitaxel-induced apoptosis. Biochem Pharmacol. 57:1215–1221.
1999.PubMed/NCBI
|
|
49
|
Lieu CH, Chang YN and Lai YK: Dual
cytotoxic mechanisms of submicromolar taxol on human leukemia HL-60
cells. Biochem Pharmacol. 53:1587–1596. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Torres K and Horwitz SB: Mechanisms of
Taxol-induced cell death are concentration dependent. Cancer Res.
58:3620–3626. 1998.PubMed/NCBI
|
|
51
|
Onoda T, Ono T, Dhar DK, Yamanoi A and
Nagasue N: Tetracycline analogues (doxycycline and COL-3) induce
caspase-dependent and -independent apoptosis in human colon cancer
cells. Int J Cancer. 118:1309–1315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Demidenko ZN, Kalurupalle S, Hanko C, Lim
CU, Broude E and Blagosklonny MV: Mechanism of G1-like arrest by
low concentrations of paclitaxel: Next cell cycle p53-dependent
arrest with sub G1 DNA content mediated by prolonged mitosis.
Oncogene. 27:4402–4410. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mäkelä M, Sorsa T, Uitto VJ, Salo T,
Teronen O and Larjava H: The effects of chemically modified
tetracyclines (CMTs) on human keratinocyte proliferation and
migration. Adv Dent Res. 12:131–135. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Myers SA and Wolowacz RG:
Tetracycline-based MMP inhibitors can prevent fibroblast-mediated
collagen gel contraction in vitro. Adv Dent Res. 12:86–93. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ryan ME, Ramamurthy NS and Golub LM:
Tetracyclines inhibit protein glycation in experimental diabetes.
Adv Dent Res. 12:152–158. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gu Y, Lee HM, Golub LM, Sorsa T, Konttinen
YT and Simon SR: Inhibition of breast cancer cell extracellular
matrix degradative activity by chemically modified tetracyclines.
Ann Med. 37:450–460. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sandler C, Ekokoski E, Lindstedt KA,
Vainio PJ, Finel M, Sorsa T, Kovanen PT, Golub LM and Eklund KK:
Chemically modified tetracycline (CMT)-3 inhibits histamine release
and cytokine production in mast cells: Possible involvement of
protein kinase C. Inflamm Res. 54:304–312. 2005. View Article : Google Scholar : PubMed/NCBI
|
